A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. - Wikidata - wikimedia - TriplyDB

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

http://www.wikidata.org/entity/Q52232631

about

Guidelines on the management of osteoporosis associated with chronic liver disease Rare diseases bullet 11: Churg-Strauss syndrome Recognizing and treating secondary osteoporosis Public health impact of adverse bone effects of oral corticosteroids Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids.Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapy Bone loss and glucocorticoid therapy in patients with respiratory disease.Metabolic bone disease in adults with inflammatory bowel disease.Recent advances: rheumatology.Interactive case report. A 66 year old woman with a rash: case outcome.Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease Links among growth factors, hormones, and nuclear factors with essential roles in bone formation.Management of glucocorticoid-induced osteoporosis in male veterans.Osteoporosis in systemic lupus erythematosus: prevention and treatment.Osteoporosis in childhood: bone density of children in health and disease.Clinical management and treatment of vasculitis.The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus.Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.Review article: monitoring for drug side-effects in inflammatory bowel disease.Patterns of bone mineral density testing: current guidelines, testing rates, and interventions Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?Updated recommendations for the diagnosis and management of osteoporosis: a local perspective Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options.What is osteoporosis?Osteopenia: a diagnostic and therapeutic challenge Intravenous pamidronate in juvenile osteoporosis.The impact of corticosteroids on growth and bone health.Management of bone disease in patients on long term glucocorticoid therapy.Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe.Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.How to prevent steroid induced osteoporosis.Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease Glucocorticosteroid-induced spinal osteoporosis: scientific update on pathophysiology and treatment.Treatment of glucocorticoid-induced osteoporsis Glucocorticoid-induced osteoporosis: treatment update and review.Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects.Proposals for prevention and management of steroid-induced osteoporosis in children and adolescents.

P2860

Q24685899-C5DE9F61-BCF2-41CA-B7D0-057DD68797F4 Q27477903-D8CF6098-F8DA-43A9-BB5C-09A316870248 Q28270738-1EB59FCA-9877-4394-ABEE-D068E31F8CC7 Q28367572-58A73293-2401-43A7-8E44-32D873C8B19A Q31000488-FED37444-ED9B-42E5-B528-0F9FCB48DEA7 Q33292103-2059F19A-65FE-4407-9CE5-EB94E98EBBF5 Q33387310-9B3ACD04-8F0F-4E93-8EBA-D002F72456C2 Q33619648-C75B44A2-A897-48A4-B6F4-4B6C197DF792 Q33714044-5A6135C3-8F9D-403A-A2E3-41DDA517D745 Q33715517-4E1B5BE2-C5FC-4C0C-839C-F41A293E83FB Q33802220-56165441-8816-447D-A0DC-C157B88B7D0A Q33814644-61A77470-1E6D-4F35-95AD-C9DF3A0CDE35 Q33869248-539AE558-1CEA-4FE3-99ED-3C820175418E Q34116002-DB241AA1-D836-40A5-AF57-A6A406D23FB1 Q34122498-6FC857E8-D840-4375-95CB-20437732A01D Q34227091-C5177328-F4E1-41F4-8EEA-010E0510580E Q34342546-D05C535B-8935-49DB-B5BA-9B1CB364400F Q34395174-D30D9DD6-B7F4-4E42-824E-8200065E2718 Q34457946-7756AFDF-1232-408E-B5CC-945A5DB90939 Q34564319-6A670AEC-4D95-457F-807B-D336AB817B9D Q34585315-F7370F4D-A20D-4A1A-B24D-711B4B26D4F3 Q34733243-48C84AB3-1FC2-4F94-8C6C-94199B952D3F Q34753158-FAFAC538-CA93-4B3D-ACEA-5F1CE631619D Q35008617-80253EA3-75BB-4CEA-BBF6-4845896A75C6 Q35026459-ECB2C3F3-0D3A-47B1-A002-CE122B039FE6 Q35107981-6BFCD29A-E3F1-4D5B-BB31-1347A88C1BEC Q35144237-D37B2F5A-33B4-463E-8B8D-FF810756DED3 Q35267359-0F003379-F2EB-425A-BB9E-1ABFF3F81CDC Q35273301-B10DB616-0056-450B-AD5A-8B9198223BA4 Q35355306-0A14109E-FC2E-437C-9F53-969C5EC01F90 Q35513823-175534A0-F33A-46EF-ADD8-94ABA8BBD23B Q35550964-2931D584-CA93-4424-A6C4-34811FC41679 Q35555248-E894FB81-089E-481E-88DA-348552D406B0 Q35579293-FAE908A6-4908-4D4C-AA19-BFC08B60376F Q35597889-1BC3D730-350C-4642-98C4-0158AFCB6A03 Q35601856-D7EDF232-6846-4D3D-B515-ABA2EC1B9EA8 Q36056932-6AC8B27E-23A9-4AE8-AC94-21DACBC344AF Q36059394-14AE5F0A-1EBD-4B60-972C-ABCE814A5875 Q36065521-7495FC75-57F3-4058-AE2A-69AECDE928A4 Q36362826-D3C8C2C7-D968-46CA-BFC5-9EDC31EED934

P2860

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

http://www.wikidata.org/entity/Q52232631

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh-hant

name

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

@en

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

@nl

type

label

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

@en

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

@nl

prefLabel

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

@en

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

@nl

P1433

Q52232631-802F57FA-0B57-4CB5-9C05-3AE82CC6C314

P1476

Q52232631-62C05ED0-BCEB-4E99-A2CA-F35DDC8A826F

P2093

Q52232631-04C07FB6-442F-4380-A831-241392FCEDB1

Q52232631-4EBBDB08-73FD-40E7-9596-5BAD6DE544D6

Q52232631-7755DDB4-B499-4D7E-842F-57090539CEB7

Q52232631-7CE245E7-FECF-4945-ADD4-D24D3C89C978

Q52232631-AF7B26D3-7841-4382-AA51-1E74D353F0EA

Q52232631-B80A8A5D-4CC2-4ACA-B1A4-2EDA84324A4C

Q52232631-B91B5AEB-4D86-4570-A55C-0323BDED257A

Q52232631-D58E2BFC-1E8E-44D7-B899-1AD66B688C15

Q52232631-DA207697-DA46-4224-82E0-F8E48793757D

Q52232631-E451E890-ED30-49F8-B634-4F36CD1DCFE5

P2860

Q52232631-0556BE83-BC9C-4D3E-80E0-A5E21FD0F4BB

Q52232631-091EA494-F730-45E2-821D-6514156030B2

Q52232631-57FDBA01-961F-42E8-8D7D-E1B22FF1A0E8

Q52232631-AD4F64E2-25A3-45E7-8847-A93668287D15

P304

Q52232631-553DE573-920E-47A8-8C95-0B485A7BFA05

P31

Q52232631-032997DD-82F4-441A-A4BC-DCF036B6E98B

P356

Q52232631-A3D513AF-4E50-4B1D-ABF0-8853BFFE1F6F

P407

Q52232631-FE638EF7-CBEA-44BD-8B62-61EA578D400D

P433

Q52232631-C66F4DD4-D463-4C38-89B8-34360FAD52FE

P478

Q52232631-BDE03E31-7DBE-40D0-98C7-8F8801DEE4CC

P50

Q52232631-187CE9B3-E91D-49ED-A9DF-AB804D028E01

Q52232631-69D6BFD7-F518-45C0-BBDF-0F391392D1E1

P577

Q52232631-0C213CA2-E058-465B-B1B7-B9DD5B2CBCE7

P5875

Q52232631-FC659AA5-7D15-409C-8DA1-AF3443DA9309

P698

Q52232631-5E35FEFC-A233-494C-A5CA-124BAF394C72

P921

Q52232631-08BE62C4-A514-4AF2-8932-3D3534103275

P356

J.1365-2796.1998.00408.X

P1433

Journal of Internal Medicine

P1476

A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update.

@en

P2093

C Cooper

http://www.w3.org/2001/XMLSchema#string

D J Hosking

http://www.w3.org/2001/XMLSchema#string

D M Reid

http://www.w3.org/2001/XMLSchema#string

D W Purdie

http://www.w3.org/2001/XMLSchema#string

I Fogelman

http://www.w3.org/2001/XMLSchema#string

J C Stevenson

http://www.w3.org/2001/XMLSchema#string

J Compston

http://www.w3.org/2001/XMLSchema#string

R Eastell

http://www.w3.org/2001/XMLSchema#string

R G Russell

http://www.w3.org/2001/XMLSchema#string

R M Francis

http://www.w3.org/2001/XMLSchema#string

P2860

Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors.

A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.

Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.

Corticosteroid-induced osteoporosis: guidelines for prevention--are they useful?

P304

271-292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2796.1998.00408.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

244

http://www.w3.org/2001/XMLSchema#string

P50

David J. Torgerson

P577

1998-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13487964

http://www.w3.org/2001/XMLSchema#string

P698

9797491

http://www.w3.org/2001/XMLSchema#string

P921